Related Experiment Video
Updated: Feb 26, 2026
06:53
Detection and Monitoring of Tumor Associated Circulating DNA in Patient Biofluids
Published on: June 8, 2019
9.3K
Nanotechnology-Assisted Molecular Profiling: Emerging Advances in Circulating Tumor DNA Detection
Jiayi Kang1,2,3, Xing Ke3, Yanan Zhao1
1College of Health Science and Technology, Shanghai Jiao Tong University School of Medicine, Shanghai, People's Republic of China.
International Journal of Nanomedicine
|February 25, 2026
Summary
Nanotechnology enhances the detection of circulating tumor DNA (ctDNA) for non-invasive cancer diagnostics. Combining nanotechnology with artificial intelligence (AI) promises to advance precision oncology through improved liquid biopsy techniques.
Area of Science:
- Biomedical Engineering
- Molecular Oncology
- Nanotechnology
Background:
- Circulating tumor DNA (ctDNA) is a key biomarker for non-invasive cancer management.
- Low ctDNA abundance and degradation necessitate highly sensitive detection methods.
- Nanotechnology offers advanced solutions for ctDNA analysis.
Purpose of the Study:
- To review recent nanotechnology-assisted strategies for ctDNA detection.
- To highlight the integration of artificial intelligence (AI) in nano-assisted liquid biopsy.
- To discuss challenges and future perspectives for clinical translation.
Main Methods:
- Surface-engineered nanomaterials for ctDNA enrichment.
- Nano-enabled signal amplification techniques.
- Integrated platforms: CRISPR, microfluidics, nanopore technologies.
- Nanostructure-based analysis of ctDNA methylation and fragmentation profiles.
- AI for nanostructure characterization, probe design, and data integration.
Main Results:
- Nanotechnology significantly improves sensitivity and robustness in ctDNA detection.
- AI integration streamlines various aspects of nano-assisted liquid biopsy.
- Nanostructure approaches enable multi-omics ctDNA analysis for enhanced diagnostics.
- Review consolidates advancements in nanotechnology for ctDNA-based precision oncology.
Conclusions:
- Converging nanotechnology and AI innovations are revolutionizing ctDNA analysis.
- These advancements hold significant potential for early cancer detection and real-time treatment monitoring.
- Addressing challenges in standardization, biocompatibility, and automation is crucial for clinical translation.
